Abstract: The present disclosure provides monoamine oxidase enzymes and methods of their use in biocatalytic processes for the preparation of substantially enantiomerically pure heterobicyclic compounds of the following structural formulas, wherein A, M, M?, and R5 are as described herein.

Abstract: Provided herein are nucleic acids, proteins, vectors, cells, kits, devices and methods useful for identifying regulatable proteins that are able to complement components of cellular signaling pathways. Also provided are compositions and methods using these complementing genes directly as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. Further provided are methods for using changes caused by expression of the complementing genes to indirectly identify associated genes to be used as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics.

Abstract: The invention relates to the microbial fermentation of gaseous substrates, particularly to gas/liquid contact modules and bioreactors configured to improve the efficiency of fermentations, particularly microbial fermentations of substrates comprising CO. In a particular embodiment, a gas/liquid contact module with multiple channels is configured to produce products in a liquid fermentation broth. In a further particular embodiment, there is provided a method of fermentation of a gaseous substrate to produce a product in a liquid fermentation broth.

Abstract: A method is provided of promoting hair growth in a subject includes applying to the skin of the subject a composition including lactoferrin in an amount effective for at least one of proliferating and activating hair follicles in the hypodermis of skin of the subject.

Abstract: The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.

Abstract: The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's) comprising the same, as the active ingredient in compositions for the treatment of pathologic disorders, preferably disorders associated with inactivation of cellular proteins involved with quality control processes, particularly, chaperones. The invention further provides methods for the treatment of such disorders and the use of the SV40 capsid proteins for the preparation of pharmaceutical compositions.

Abstract: The invention relates to a method for utilizing low-quality tail gas derived from a pressure swing adsorption system or membrane system, which is used to upgrade biogas, as a beneficial fuel for the facility and/or digester boiler.

Abstract: The present invention discloses cell permeable Nanog and Oct4 recombinant proteins that comprise a kaposi fibroblast growth factor 4 (kFGF4)-derived macromolecule transduction domain (MTD). Also disclosed are polynucleotides encoding the cell permeable Nanog and Oct4 recombinant proteins, a method of increasing self-renewal and suppressing differentiation of stem cells by treating the cells in combination with the cell permeable Nanog and Oct4 recombinant proteins, and the combined use of the cell permeable Nanog and Oct4 recombinant proteins for increasing self-renewal and suppressing differentiation of stem cells.

Abstract: The present invention provides methods of designing and generating polypeptide variants that have altered properties compared to a parent polypeptide. The present invention further provides a computer program product for carrying out the design of a variant polypeptide. The present invention further provides nucleic acids encoding enzyme variants, as well as vectors and host cells comprising the nucleic acids. The present invention further provides variant enzymes; methods of producing the variant enzymes; and methods of producing compounds using the enzymes.

Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The at least one other chemopreventive agent may comprise an antiestrogen such as Tamoxifen. The compositions of the invention may be used to prevent the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.

Abstract: The invention provides Sp35 polypeptides and fusion proteins thereof, Sp35 antibodies and antigen-binding fragments thereof and nucleic acids encoding the same. The invention also provides compositions comprising, and methods for making and using, such Sp35 antibodies, antigen-binding fragments thereof, Sp35 polypeptides and fusion proteins thereof.

Abstract: The present invention relates to a process enhancing the extraction of phytochemicals from plant materials using pulsed electric field. The process is also used with a step of pressing, wherein the pressing and the pulse electric field treatment can be accomplished in a unique treatment chamber.

Abstract: The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 kinase.

Abstract: A method of measuring the ability of a biological sample to withstand reactive oxygen species (ROSs). The method includes at least the steps of putting the sample for testing and a photosensitive agent in a liquid medium into contact so as to form a mixture for testing, subjecting the mixture for testing to a dose of light irradiation so as to give rise, by photochemical reaction, to the production of reactive oxygen species, then after irradiation, adding a compound that reacts colorimetrically in the presence of reactive oxygen species (ROSs) to form a chromogen or fluorescent substance, and measuring the quantity of chromogen or fluorescent substance that is produced, and also subjecting a reference mixture to the same photochemical, colorimetric, and measurement reactions as the mixture for testing.

Abstract: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types.

Abstract: The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.

Abstract: The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation, process of preparation and the method of use including supplementing blood volume in mammals and treating disorders in mammals where oxygen delivery agents are of benefit.

Abstract: The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and Statherin fusion proteins (STAT-LF) along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.

Abstract: The invention provides a high affinity heme-binding agent, which can be provided in the form of a pharmaceutical composition that includes, optionally, a pharmaceutically acceptable carrier. The heme-binding agent can be used in a method of facilitating heme-iron export from a cell. The method comprises contacting a cell with a high affinity heme-binding agent. Also provided is a method of treating a disorder associated with excess iron in cells in a subject. The method comprises administering to the subject an effective amount of the composition of the invention. The subject is typically a mammal, most typically a human or veterinary subject.

Abstract: The present invention relates to the use of a screening method for identifying candidate molecules that can be used for the treatment of respiratory conditions in a mammal, wherein the screening method comprises a step which comprises determining whether the functional activity of a TASK-2 polypeptide in the presence of a test molecule is decreased or eliminated compared with the functional activity of the TASK-2 polypeptide in the absence of the test molecule, the test molecule being considered to be a candidate molecule when it decreases or eliminates the functional activity.